Regarding the issuance of stock acquisition rights by third-party allotment, the use of proceeds and scheduled expenditure timing disclosed in December 2025 and March 2026 have been revised. Major changes include a reallocation of development expenses for regenerative medicine products, an increase in research expenses related to specific cell-processed products, and substantive changes in expenditure timing. The total fund amount remains unchanged at 1,849 million yen, and the management method for unallocated funds is also specified.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2370","jir_company_name":"MEDINET Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-10-30","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/2370-20261030-01.pdf","jir_short_summary":"Regarding the issuance of stock acquisition rights by third-party allotment, the use of proceeds and scheduled expenditure timing disclosed in December 2025 and March 2026 have been revised. Major changes include a reallocation of development expenses for regenerative medicine products, an increase in research expenses related to specific cell-processed products, and substantive changes in expenditure timing. The total fund amount remains unchanged at 1,849 million yen, and the management method for unallocated funds is also specified.","jir_summary":"### Overview of Change in Use of Proceeds\nThe company has revised the disclosed use of proceeds for the issuance of stock acquisition rights by third-party allotment previously announced in December 2025 and March 2026. The total fund amount remains unchanged at 1,849 million yen; however, (i) the allocation and timing for development expenses for regenerative medicine products and (ii) the allocation and timing for technology and clinical research expenses related to specific cell-processed products have been changed, and (iv) head office working capital will continue to be allocated over the period from December 2025 to December 2026. Unallocated amounts continue to be managed.\n\n### Impact on Shareholders and Future Outlook\nThis change reflects a reallocation of funds accompanying a review of R&D policy and a focus on clinical application areas. It is stated that there is no immediate impact on the fiscal results, and reflection in earnings guidance for fiscal years from 2027 onward will be considered in future disclosed earnings forecasts. The company will promptly disclose any new relevant information as it arises.","jir_financial_highlights":"Total funds raised: 1,849 million yen (Unknown)\nUse of proceeds before change: Development expenses for regenerative medicine products 1,055 million yen, Promotion expenses 196 million yen, Head office working capital 598 million yen (Moved to post-change uses)\nUse of proceeds after change: Development expenses for regenerative medicine products 400 million yen, Costs for introduction of new technologies etc. related to specific cell-processed products 655 million yen, Head office working capital 598 million yen (Partially changed allocation and newly set periods)","jir_category":"","jir_hashtags":"#MEDINET, #DisclosureChange, #StockAcquisitionRights, #UseOfProceedsChange","jir_key_figures":"Total funds raised: 1,849 million yen\nUses before change: Total 3 items (total 1,849 million yen)\nUses after change: 4 items (total 1,849 million yen)","jir_meta_title":"MEDINET Co., Ltd. \u2014 Change in Disclosure: Change in Use of Proceeds for Third-Party Allotment Stock Acquisition Rights","jir_meta_description":"MEDINET Co., Ltd. announced changes to the use of proceeds and expenditure timing related to the issuance of stock acquisition rights by third-party allotment. Allocations for regenerative medicine-related costs and research investment in specific cell-processed products have been revised, and the head office working capital allocation period has been updated. No impact on current financial results.","jir_og_title":"MEDINET Co., Ltd. \u2014 Notice of Change in Use of Proceeds","jir_og_description":"Changed the use of proceeds and scheduled expenditure timing for stock acquisition rights issued by third-party allotment. Reallocated regenerative medicine-related expenses and research expenses for specific cell-processed products. No direct impact on financial results; reflection in future earnings guidance will be considered.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":122814,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"disclosure_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-138821","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n